Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy by Aspelund et al. (2011) Diabetologia 54:2525-2532.
作者信息
McGhee Sarah, Harding Simon P, Wong David
出版信息
Graefes Arch Clin Exp Ophthalmol. 2012 Apr;250(4):477-8. doi: 10.1007/s00417-012-1939-2. Epub 2012 Mar 10.
Abstract
摘要
相似文献
1
Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy by Aspelund et al. (2011) Diabetologia 54:2525-2532.
Graefes Arch Clin Exp Ophthalmol. 2012 Apr;250(4):477-8. doi: 10.1007/s00417-012-1939-2. Epub 2012 Mar 10.
2
Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy.
Diabetologia. 2011 Oct;54(10):2525-32. doi: 10.1007/s00125-011-2257-7. Epub 2011 Jul 27.
3
The role of retinopathy distribution and other lesion types for the definition of examination intervals during screening for diabetic retinopathy.
Acta Ophthalmol. 2017 Jun;95(4):400-404. doi: 10.1111/aos.13334. Epub 2016 Nov 19.
4
Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs.
Br J Ophthalmol. 2016 May;100(5):683-7. doi: 10.1136/bjophthalmol-2015-307341. Epub 2015 Sep 16.
5
Diabetic eye screening with variable screening intervals based on individual risk factors is safe and effective in ophthalmic practice.
Acta Ophthalmol. 2020 Jun;98(4):343-346. doi: 10.1111/aos.14425. Epub 2020 Mar 25.
6
The preferences of people with diabetes for diabetic retinopathy screening.
Diabet Med. 2012 Jul;29(7):836-7. doi: 10.1111/j.1464-5491.2012.03630.x.
7
Diabetes in Africa: screening for diabetic retinopathy.
Eur J Intern Med. 2010 Jun;21(3):145-6. doi: 10.1016/j.ejim.2010.02.010. Epub 2010 Mar 30.
8
Diabetic retinopathy screening: experiences from northern Tanzania.
Lancet Diabetes Endocrinol. 2016 Jan;4(1):10-2. doi: 10.1016/S2213-8587(15)00422-2. Epub 2015 Dec 3.
9
Screening for diabetic retinopathy.
Diabetes Care. 2001 Mar;24(3):419-20. doi: 10.2337/diacare.24.3.419.
10
Response to Malone et al.
Diabetes Care. 2001 Sep;24(9):1698-9. doi: 10.2337/diacare.24.9.1698.
引用本文的文献
1
To Determine the Risk-Based Screening Interval for Diabetic Retinopathy: Development and Validation of Risk Algorithm from a Retrospective Cohort Study.
Diabetes Metab J. 2025 Mar;49(2):286-297. doi: 10.4093/dmj.2024.0142. Epub 2024 Oct 31.
2
Individualised risk assessment for diabetic retinopathy and optimisation of screening intervals: a scientific approach to reducing healthcare costs.
Br J Ophthalmol. 2016 May;100(5):683-7. doi: 10.1136/bjophthalmol-2015-307341. Epub 2015 Sep 16.
3
Extending the diabetic retinopathy screening interval beyond 1 year: systematic review.
Br J Ophthalmol. 2016 Jan;100(1):105-14. doi: 10.1136/bjophthalmol-2014-305938. Epub 2015 Jan 13.
本文引用的文献
1
Intensive glycaemic control for patients with type 2 diabetes: systematic review with meta-analysis and trial sequential analysis of randomised clinical trials.
BMJ. 2011 Nov 24;343:d6898. doi: 10.1136/bmj.d6898.
2
Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy.
Diabetologia. 2011 Oct;54(10):2525-32. doi: 10.1007/s00125-011-2257-7. Epub 2011 Jul 27.
3
Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme.
Diabet Med. 2009 Oct;26(10):1040-7. doi: 10.1111/j.1464-5491.2009.02820.x.
4
UKPDS-modelling of cardiovascular risk assessment and lifetime simulation of outcomes.
Diabet Med. 2008 Aug;25 Suppl 2:41-6. doi: 10.1111/j.1464-5491.2008.02498.x.
5
UKPDS 50: risk factors for incidence and progression of retinopathy in Type II diabetes over 6 years from diagnosis.
Diabetologia. 2001 Feb;44(2):156-63. doi: 10.1007/s001250051594.
Zotero 插件